Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
180 Life Sciences Corp. Common Stock (symbol: ATNF) represents a pioneering clinical-stage biotechnology company based in Menlo Park, California. The company focuses on developing innovative therapeutics to address unmet medical needs in chronic pain, inflammation, and fibrosis.
The company has several key product development platforms currently in Phase IIb/III clinical trials:
- Fibrosis and Anti-TNF Platform: This platform targets the treatment of fibrosis and anti-tumor necrosis factors, a major cause of inflammation.
- Synthetic Cannabidiol (CBD) Analogs Platform: This platform includes man-made derivatives of CBD designed to offer therapeutic benefits.
- α7nAChR Platform: Focused on the alpha 7 nicotinic acetylcholine receptor, which plays a role in modulating inflammation and pain.
180 Life Sciences Corp. is committed to advancing its drug candidates through robust clinical trials and cutting-edge research. From addressing postoperative pain relief with orally absorbed CBD tablets to combating chronic inflammation and fibrosis, the company's innovative approach highlights its significance in the biotechnology landscape.
The company’s recent achievements include a notable presentation by Dr. Michael J. Alaia at the 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The talk focused on the efficacy of CBD tablets for postoperative pain relief, showcasing the potential impact of 180 Life Sciences Corp.'s therapies.
For more information, investors can contact Jason Assad, Director of Investor Relations, at jassad@180lifesciences.com.
180 Life Sciences Corp. (NASDAQ: ATNF) has appointed Pamela Marrone, PhD, and Frank Knuettel II, MBA, to its Board of Directors, effective upon the earlier of the filing of the 2020 Form 10-K or June 28, 2021. Dr. Marrone brings over 30 years of experience in biotech, including notable success with Marrone Bio Innovations, with a 5-year revenue CAGR of ~30%. Knuettel has over 25 years in management and finance, previously serving in significant roles within cannabis companies. CEO James Woody expressed confidence that their distinct skill sets will enhance shareholder value.
180 Life Sciences Corp. (ATNF) announced management's presentation at the LD Micro Invitational XI, set for June 10, 2021, at 1:30 p.m. EDT. The virtual event will allow investors to hear insights from CEO Dr. James Woody. The conference runs from June 8-10, 2021, and a live audio webcast will be available. 180 Life Sciences focuses on developing innovative drugs for inflammatory diseases, fibrosis, and pain, collaborating with experts from prestigious institutions like Oxford and Stanford.
180 Life Sciences Corp. (NASDAQ: ATNF) announced the appointment of Russell T. Ray and Teresa DeLuca, MD, MBA, to its Board of Directors, effective June 15, 2021. Russell Ray has extensive experience in corporate finance within the healthcare sector, previously serving at Credit Suisse and as a venture partner. Teresa DeLuca brings over 20 years of healthcare management expertise, including roles at Fortune 50 companies and Columbia University. The additions aim to enhance board governance and satisfy Nasdaq’s independent director requirements, thereby potentially increasing shareholder value.
180 Life Sciences Corp. (NASDAQ: ATNF) has successfully collected and submitted all patient data from its Phase 2b clinical trial for Dupuytren’s disease, conducted in partnership with the University of Oxford. The trial involved 181 patients and analyzed the efficacy of adalimumab, administered over a series of injections. Despite delays due to the COVID-19 pandemic, data analysis is underway, with results expected to be released in Q4 2021. This trial addresses a significant medical need, as no current approved therapies exist for early-stage Dupuytren’s disease, potentially impacting patient quality of life.
180 Life Sciences Corp. (NASDAQ: ATNF) announced that it received a notification from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the pending filing of its 2020 Form 10-K. The letter does not immediately impact trading on Nasdaq. The company is currently addressing delays in financial statements following amended filings for its predecessor and a recent SEC statement on warrants. 180 Life Sciences has until June 15, 2021, to file the 10-K and may seek a plan to regain compliance if delayed further, risking potential delisting.
180 Life Sciences Corp. (NASDAQ: ATNF) announced that Dr. Lynn Williams received the International Dupuytren Award 2021 for her research published in 2020, identifying collagen VI as a target in fibrotic diseases. This research, sponsored by 180 Life Sciences, is now the foundation of their preclinical studies aimed at developing new therapies for fibrosis. CEO Dr. James Woody highlighted the significance of this award-winning work in providing insights into potential therapeutic targets.
180 Life Sciences Corp. (NASDAQ: ATNF) has announced a new broadcast titled, “Controlling Inflammation to Stop Disease.” The company's research focuses on anti-TNF antibodies for autoimmune inflammatory diseases, suggesting significant market growth potential as new uses are identified. Ongoing clinical trials aim to address various disorders linked to inflammation. Collaborating with renowned institutions, 180 Life Sciences seeks to innovate treatments for unmet medical needs in inflammatory diseases. The company's lead program is currently in phase 2b/3 trials.
180 Life Sciences Corp. (NASDAQ: ATNF) has been featured in a NetworkNewsWire editorial titled "Controlling Inflammation to Stop Disease." This editorial highlights the significant link between inflammation and various health issues, which account for over 50% of global deaths. 180 Life Sciences is at the forefront of developing anti-inflammatory drugs, with its lead program in phase 2b/3 trials. The company is leveraging expertise from prestigious institutions like Oxford University and Stanford to create innovative therapies targeting unmet needs in inflammatory diseases, fibrosis, and pain.
180 Life Sciences Corp (NASDAQ: ATNF) outlines progress in a letter to stockholders from CEO Dr. James Woody. The company has successfully restated prior financials, completed an $11.7 million private placement, and reduced convertible debt from over $5 million to $316,000. They are adding independent directors to comply with NASDAQ requirements and aim to expedite clinical trials funded by grants. The pipeline includes a Phase 2b/3 trial for Dupuytren's contracture with expected results in the second half of 2021, targeting a market of over 22 million people in the US and EU.
180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology firm, announced its participation in the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. CEO Dr. James Woody will engage in one-on-one meetings with investors. The company focuses on innovative drug development targeting inflammatory diseases, fibrosis, and pain, with its lead program currently in Phase 2b/3 trials.
FAQ
What is the current stock price of 180 Life Sciences (ATNF)?
What is the market cap of 180 Life Sciences (ATNF)?
What does 180 Life Sciences Corp. specialize in?
Where is 180 Life Sciences Corp. headquartered?
What are the key platforms of 180 Life Sciences Corp.?
What stage are the company's product development platforms in?
Who can be contacted for investor relations?
What is the focus of the recent talk presented by Dr. Michael J. Alaia?
What is the company's ticker symbol?
What unmet medical needs does 180 Life Sciences Corp. aim to address?
What is the significance of the α7nAChR platform?
How can I stay updated with the latest news about 180 Life Sciences Corp.?
